Alpha 2.0
Login Register
» Authors » Kathleen Blondeau

Kathleen Blondeau

Explore the profile of Kathleen Blondeau including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 549
Followers 0
Related Specialties
Gastroenterology
Pulmonary Medicine
General Surgery
Top 10 Co-Authors
Daniel Sifrim
Jan Tack
Veerle Mertens
Ans Pauwels
Ricard Farre
Lieven J Dupont
Jillian Smith
Kaycee M Sink
Lieven Dupont
Susanne Ostrowitzki
Published In
Am J Gastroenterol
Gut
Dig Dis
J Heart Lung Transplant
Clin Gastroenterol Hepatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Habib A, Zhao C, Aban I, Franca Jr M, Jose J, Meyer Zu Horste G, et al.
Lancet Neurol . 2025 Jan; 24(2):117-127. PMID: 39862880
Background: Evidence from preclinical studies suggests that IL-6 signalling has the potential to modulate immunopathogenic mechanisms upstream of autoantibody effector mechanisms in patients with generalised myasthenia gravis. We aimed to...
2.
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials
Ostrowitzki S, Bittner T, Sink K, Mackey H, Rabe C, Honig L, et al.
JAMA Neurol . 2022 Sep; 79(11):1113-1121. PMID: 36121669
Importance: Alzheimer disease (AD), a neurodegenerative disease characterized by β-amyloid plaques and τ tangles in the brain, represents an unmet medical need with no fully approved therapeutics to modify disease...
3.
Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers
Dolton M, Chesterman A, Moein A, Sink K, Waitz A, Blondeau K, et al.
Clin Pharmacol Ther . 2021 Aug; 110(5):1337-1348. PMID: 34347883
Compared with intravenous formulations, subcutaneous (s.c.) formulations of therapeutic monoclonal antibodies may provide increased patient access and more convenient administration options, although historically high-volume s.c. administration (> 10-15 mL) has...
4.
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks
Guthrie H, Honig L, Lin H, Sink K, Blondeau K, Quartino A, et al.
J Alzheimers Dis . 2020 Jun; 76(3):967-979. PMID: 32568196
Background: Crenezumab is a fully humanized, monoclonal anti-amyloid-β immunoglobulin G4 antibody. Objective: This Phase Ib study (NCT02353598) evaluated the safety, tolerability, and pharmacokinetics of crenezumabat doses of ≤120 mg/kg administered...
5.
Evolving pharmacological approaches in gastroesophageal reflux disease
Altan E, Blondeau K, Pauwels A, Farre R, Tack J
Expert Opin Emerg Drugs . 2012 Jul; 17(3):347-59. PMID: 22834684
Introduction: Proton pump inhibitors (PPIs) have considerably improved quality of life in patients with gastroesophageal reflux disease (GERD). However, many patients remain symptomatic despite standard PPI therapy. Areas Covered: This...
6.
Mechanisms of increased gastroesophageal reflux in patients with cystic fibrosis
Pauwels A, Blondeau K, Dupont L, Sifrim D
Am J Gastroenterol . 2012 Jul; 107(9):1346-53. PMID: 22777342
Objectives: Up to 80% of patients with cystic fibrosis (CF) may have increased gastroesophageal reflux (GER). It has been suggested that increased GER is due to low basal lower esophageal...
7.
Bile acids in sputum and increased airway inflammation in patients with cystic fibrosis
Pauwels A, Decraene A, Blondeau K, Mertens V, Farre R, Proesmans M, et al.
Chest . 2011 Dec; 141(6):1568-1574. PMID: 22135379
Background: Up to 80% of patients with cystic fibrosis (CF) may have increased gastroesophageal reflux and aspiration of duodenogastric contents into the lungs. We aimed to assess aspiration in patients...
8.
Baclofen improves symptoms and reduces postprandial flow events in patients with rumination and supragastric belching
Blondeau K, Boecxstaens V, Rommel N, Farre R, Depeyper S, Holvoet L, et al.
Clin Gastroenterol Hepatol . 2011 Nov; 10(4):379-84. PMID: 22079512
Background & Aims: In patients with clinically suspected rumination, esophageal impedance manometry differentiates episodes of rumination (involuntary straining with intragastric pressure increases) from aerophagia/supragastric belching. Treatment options are limited and...
9.
Conservative management of esophageal perforations during pneumatic dilation for idiopathic esophageal achalasia
Vanuytsel T, Lerut T, Coosemans W, Vanbeckevoort D, Blondeau K, Boeckxstaens G, et al.
Clin Gastroenterol Hepatol . 2011 Nov; 10(2):142-9. PMID: 22064041
Background & Aims: Esophageal perforation is the most serious adverse event of pneumatic dilation (PD) for achalasia; it is usually managed by surgical repair. We investigated risk factors for esophageal...
10.
Interobserver and intraobserver variability in pH-impedance analysis between 10 experts and automated analysis
Loots C, van Wijk M, Blondeau K, Dalby K, Peeters L, Rosen R, et al.
J Pediatr . 2011 Sep; 160(3):441-446.e1. PMID: 21924738
Objective: To determine interobserver and intraobserver variability in pH-impedance interpretation between experts and accuracy of automated analysis (AA). Study Design: Ten pediatric 24-hour pH-impedance tracings were analyzed by 10 observers...